Due diligence: On surrogate advertising
Curbs on surrogate advertising must avoid regulatory overreach
Maharashtra Food and Drug Administration (FDA) Commissioner Tukaram Mundhe's efforts to dismantle the marketing tactics that involve surrogating tobacco products through celebrity endorsements are a promising step in the right direction. This approach comes at a time when the advertising industry for consumer goods has been grappling with the issue of an unequal power dynamic, where the individuals with persuasive influence often face negligible repercussions for promoting certain products. The situation is further exacerbated by the inequities present in the public healthcare system.
While the FDA's suspicion that Vimal Elaichi, endorsed by Shah Rukh Khan, Ajay Devgn, and Tiger Shroff, lacks a distinct market identity independent of its association with tobacco is reasonable, given the provisions under the Cigarettes and Other Tobacco Products Act (COTPA) Rules, the Delhi High Court in DGHS vs Som Pan Product Pvt.
Ltd. (2024) emphasized the state's responsibility to prove a case of surrogate advertising. This means that mere brand registration or the existence of a technically legal product cannot single-handedly establish surrogate advertising.
Mundhe's endeavors, although commendable, should be backed by thorough investigations under COTPA and the Food Safety and Standards Act 2006 to withstand legal scrutiny. India remains the world's largest victim of oral cancer, and the FDA is justified in treating specific advertisements as unfair trade practices, posing significant threats to consumer health.
The introduction of endorser liability under the Consumer Protection Act 2019, along with substantial financial penalties, has also diminished celebrities' ability to claim ignorance of a manufacturer's intentions as a valid defense.
Building upon this principle, the FDA's decision to require celebrity endorsers to justify their choices is a logical extension in the enforcement domain. However, the tobacco issue echoes across other products making unsubstantiated claims, such as those promoting immunity enhancement, and educational or financial services. Regrettably, India's regulatory framework is convoluted, with numerous Acts and Rules governing different aspects.
Consequently, many misleading advertisements often exploit legal and administrative loopholes to seek judicial intervention.
If the FDA fails to act impartially, it could further exacerbate the regulatory overreach problem, inadvertently bolstering the very practices it aims to eradicate.
Written by urgent.news from The Hindu - Sci-Tech's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
- Due diligence: On surrogate advertising thehindu.com